Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Viridian Therapeutics, Inc.\DE (VRDN) Receivables - Other: 2016-2023

Historic Receivables - Other for Viridian Therapeutics, Inc.\DE (VRDN) over the last 5 years, with Dec 2023 value amounting to $102,000.

  • Viridian Therapeutics, Inc.\DE's Receivables - Other rose 499900.00% to $70.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $70.0 million, marking a year-over-year increase of 499900.00%. This contributed to the annual value of $102,000 for FY2023, which is negligibly% changed negligibly from last year.
  • Viridian Therapeutics, Inc.\DE's Receivables - Other amounted to $102,000 in FY2023, which was down 0.00% from $102,000 recorded in FY2022.
  • Over the past 5 years, Viridian Therapeutics, Inc.\DE's Receivables - Other peaked at $451,000 during FY2021, and registered a low of $102,000 during FY2022.
  • For the 3-year period, Viridian Therapeutics, Inc.\DE's Receivables - Other averaged around $218,333, with its median value being $102,000 (2023).
  • Data for Viridian Therapeutics, Inc.\DE's Receivables - Other shows a maximum YoY crashed of 77.38% (in 2022) over the last 5 years.
  • Over the past 3 years, Viridian Therapeutics, Inc.\DE's Receivables - Other (Yearly) stood at $451,000 in 2021, then crashed by 77.38% to $102,000 in 2022, then remained steady at $102,000 in 2023.